AI company strikes deal with AstraZeneca

Charlie Spargo's picture

Pharmaceutical giant AstraZeneca and BenevolentAI have completed a long-term deal to use their technology for the discovery and development of treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

The Cambridge-based AI and machine learning company - which has raised more than $200 million to work on the full process from drug discovery to clinical development - will collaborate with the pharmaceutical corporation, drawing on their genomics, chemistry and clinical data in order to create a “network of contextualised scientific data”.

Joanna Shields, CEO of BenevolentAI, said: “Millions of people today suffer from diseases that have no effective treatment.

"The future of drug discovery and development lies in bridging the gap between AI, data, and biology. We are thrilled to be joining forces with AstraZeneca to develop new insights and identify promising new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.”